SARASOTA, Fla., Feb. 3, 2022 /PRNewswire/ -- INVO
Bioscience, Inc. (NASDAQ: INVO) ("Company") ("INVO"), a
commercial-stage fertility company focused on expanding access to
advanced treatment worldwide with its INVOcell® medical device and
the IVC procedure it enables, provides a commercialization
update.
Effective February 1, 2022, INVO
regained full U.S. commercialization rights to its INVOcell
technology, enabling the Company to sell directly into existing IVF
clinics, to expand the number of INVO Centers free of any
limitations, and to pursue its market expansion strategy focused on
increasing access to care and democratizing fertility care for
underserved patients.
Today, the global fertility market is a multi-billion industry,
yet remains severely underserved, with estimates suggesting more
than 90% of couples in need of infertility treatment going without
care. INVO believes INVOcell and the IVC procedure are well
suited to address existing industry capacity challenges and provide
an affordable and effective fertility option for patients in
need.
Mike Campbell, COO and V.P.
Business Development of INVO stated, "We are now able to
synchronize and take an expanded, more comprehensive and direct
approach toward our U.S. commercialization efforts. In
addition to supporting and expanding upon the approximate 100 U.S.
IVF clinics that have trained on the INVOcell device and the IVC
treatment process for their operation, we expect to advance our
INVO Center efforts as a critical part of the U.S. strategy moving
forward. With our initial three centers now fully operational
and focused on delivering INVOcell and the IVC procedure, we are
excited to continue rolling out additional centers. As
previously noted, we have initially identified over 20 cities in
the U.S. as attractive markets. We believe our multi-channel
commercial strategy of supporting, servicing, and expanding across
the existing IVF clinic network as well as building new, dedicated
INVO Centers will help drive increased market awareness of our
revolutionary technology, and provide a viable option to help
served the large, underserved patient population"
Steve Shum, CEO of INVO, added,
"The underserved market is a key opportunity for INVOcell and our
focus. Democratizing fertility has been and will remain a key
part of our Company's mission. We are pleased with the trends and
progress at our newly operational INVO Centers and expect 2022 to
continue to be transformative as we look to further unlock the
value of our breakthrough technology. A tremendous foundation
has been built over the years in many core areas supportive of
expanded commercialization and we look forward to leveraging and
capitalizing on this groundwork moving forward."
Key Commercial Initiatives for 2022:
- Increase distribution activities (selling the INVOcell
device to existing clinics). This includes selling direct
here in the U.S. market and focusing on the existing, previously
signed international distributors. We have added a dedicated
resource for the U.S. effort along with important support services
such as training and education.
- Drive strong patient volumes within the existing INVO
Centers in North
America. With key personnel and supportive
agencies in place and active, we are expanding our marketing and
public relations efforts to complement and accelerate the progress
and market awareness at our joint-venture operating INVO Centers in
Birmingham, AL, Atlanta, GA, & Monterey, Mexico.
- Build additional INVO Centers. We have identified
specific markets and details will be forthcoming.
- Develop our lab services model targeted to support the
OB/GYN market. As previously highlighted, Dr. Barbara
Levy, M.D., FACOG, FACS, a highly influential clinical executive,
joined our team as Senior VP Global Clinical Integration to help
guide this effort in collaboration with our commercial and medical
team.
INVO expects to provide additional updates on these key areas in
the near future.
About INVOcell
The INVOcell procedure is the first in-vivo culture (IVC) system
in the world used for the incubation of eggs and sperm during
fertilization and early embryo development within the body, as an
alternative to conventional In Vitro Fertilization (IVF) and
Intrauterine Insemination (IUI). Through its in vivo approach,
INVOcell offers patients a more natural and intimate experience
with comparable results at a lower cost.
About INVO Bioscience, Inc.
We are a commercial-stage fertility company expanding access to
advanced treatment worldwide. Our primary mission is to implement
new medical technologies aimed at increasing the availability of
affordable, high-quality, patient-centered fertility care. Our
patented medical device, the INVOcell®, enables the INVO®
Procedure, a revolutionary in vivo method of vaginal
incubation. This treatment solution is the world's first
intravaginal culture technique for the incubation of oocytes
and sperm during fertilization and early embryo development. This
technique, designated as "IVC," provides patients a more natural
and intimate experience in comparison to other assisted
reproductive technology (ART) treatments. The INVO® Procedure
can deliver comparable results at a fraction of the cost of
traditional in vitro fertilization (IVF) and is a
significantly more effective treatment than intrauterine
insemination (IUI). Our commercialization strategy
involves the opening of dedicated INVO Centers focused on offering
the INVOcell and IVC procedure (with 3 centers in North America now operational), as well as
selling our technology solution into existing fertility
clinics. For more information, please visit
www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation
to (and expressly disclaim any such obligation to) update or alter
our forward-looking statements, whether as a result of new
information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-expands-us-commercialization-efforts-301474563.html
SOURCE INVO Bioscience, Inc.